[Efficacy and safety of the use of levodropropizine in patients with chronic interstitial lung diseases].

Abstract

Efficacy and tolerability of an antitussive drug, levodropropizine, in 21 adult patients with interstitial lung disorders was evaluated in this study. Levodropropizine dosage was 60 mg t.i.d. for four days of therapy. The authors evaluated the effectiveness of the antitussive therapy and, on the other hand, the tolerability of levodropropizine in these patients, monitoring PaO2, PaCO2 and pH values. The changes in cough frequency (34.1 +/- 5.6 20.4 +/- 5.4 mean +/- d.s. before and after treatment) and the overall efficacy judgment as reported by the doctor indicate a decrease in cough as confirmed by the significance of Kruskal-Wallis test (p less than 0.05). Furthermore the tolerability has been excellent, because the PaO2, PaCo2 ad pH values before and after treatment were unchanged (PaO2 mmHg: basal 71 +/- 16.6, after treatment 73.8 +/- 14.2; PaCO2 mmHg: basal 36.6 +/- 5, after treatment 36.6 +/- 4.6; pH basal 7.4 +/- 0.03, after treatment 7.4 +/- 0.02).

• Authors: G Gunella, A Zanasi, C B Massimo Vanasia
• Journal: La Clinica terapeutica (Clin Ter) Vol. 136 Issue 4 Pg. 261-6 (Feb 28 1991) ISSN: 0009-9074 [Print] Italy
• Vernacular Title: Efficacia e sicurezza di impiego di levodropropizina in pazienti affetti da pneumopatie interstiziali croniche.
• PMID: 1827388 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Antitussive Agents
• Propylene Glycols
• dipropizine

Topics

• Adult
• Aged
• Aged, 80 and over
• Antitussive Agents (administration & dosage, therapeutic use)
• Drug Evaluation
• Drug Tolerance
• Female
• Humans
• Lung Diseases (drug therapy)
• Male
• Middle Aged
• Propylene Glycols (administration & dosage, therapeutic use)
• Pulmonary Fibrosis (drug therapy)
• Sarcoidosis (drug therapy)